Looking at the seemingly contradictory role of vinblastine in anaplastic large-cell lymphoma from a metronomic perspective

Journal of Clinical Oncology

Volumn 29, Issue 4, 2011, Pages

  André, Nicolas ^a   Pasquier, Eddy ^b   Gentet, Jean Claude ^a   Kamen, Barton A ^c  

^a TIMONE HOSPITAL   (France)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILDHOOD CANCER; DRUG EFFICACY; HUMAN; LARGE CELL LYMPHOMA; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT DURATION; TUMOR IMMUNITY;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; TREATMENT OUTCOME; TUMOR ESCAPE; VINBLASTINE;

EID: 79952079442     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.2883     Document Type: Letter

References (17)

1. Le Deley MC, Rosolen A, Williams DM, et al: Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: Results of the randomized ALCL99-vinblastine trial. J Clin Oncol 28:3987-3993, 2010
2. Brugières L, Quartier P, Le Deley MC, et al: Relapses of childhood anaplastic large-cell lymphoma: Treatment results in a series of 41 children - A report from the French Society of Pediatric Oncology. Ann Oncol 11:53-58, 2000 (Pubitemid 30084579)
3. Brugières L, Pacquement H, Le Deley MC, et al: Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: A report from the French Society of Pediatric Oncology. J Clin Oncol 27:5056-5061, 2009
4. Pasquier E, Kavallaris M, André N: Metronomic chemotherapy: New rationale for new directions. Nat Rev Clin Oncol 7:455-465, 2010
5. Pasquier E, André N, Braguer D: Targeting microtubules to inhibit angiogenesis and disrupt tumor vasculature: Implications for cancer treatment. Curr Cancer Drug Targets 7:566-581, 2007 (Pubitemid 47358143)
6. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436, 2004 (Pubitemid 38745528)
7. Mabeta P, Pepper MS: A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents. Angiogenesis 12:81-90, 2009
8. Bertolini F, Paul S, Mancuso P, et al: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342-4346, 2003 (Pubitemid 36951001)
9. Abdollahi A, Folkman J: Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 13:16-28, 2010
10. Zitvogel L, Apetoh L, Ghiringhelli F, et al: The anticancer immune response: Indispensable for therapeutic success? J Clin Invest 118:1991-1200, 2008
11. Tanaka H, Matsushima H, Nishibu A, et al: Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res 69:6987-6994, 2009
12. Schirrmacher V: T-cell immunity in the induction and maintenance of a tumour dormant state. Semin Cancer Biol 11:285-295, 2001
13. Mahnke YD, Schwendemann J, Beckhove P, et al: Maintenance of long-term tumour-specific T-cell memory by residual dormant tumor cells. Immunology 115:325-336, 2005 (Pubitemid 40896031)
14. Kamen BA: Serendipity - Methotrexate and 6 mercaptopurine for continuation therapy for patients with acute lymphoblastic leukemia: The leukemic stem cell and beyond? J Pediatr Hematol Oncol 31:383-384, 2009
15. Gatenby RA: A change of strategy in the war on cancer. Nature 459:508, 2009
16. André N, Pasquier E: For cancer, seek and destroy or live and let live? Nature 460:324, 2009
17. Stempak D, Gammon J, Halton J, et al: A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 28:720-728, 2006 (Pubitemid 44786435)